Håndtering af hjertekomplikationer sekundært til medicinsk kræftbehandling

Ann Banke; Anne Polk; Dorte Nielsen; Lars Videbæk; Ulrik Overgaard; Emil Loldrup Fosbøl; Merete Vaage-Nielsen; Kirsten Melgaard Nielsen; Morten Schou

Håndtering af hjertekomplikationer sekundært til medicinsk kræftbehandling

Ann Banke, Anne Polk, Dorte Nielsen, Lars Videbæk, Ulrik Overgaard, Emil Loldrup Fosbøl, Merete Vaage-Nielsen, Kirsten Melgaard Nielsen, Morten Schou

Abstract

As the prognoses of both heart and cancer patients have improved along with a longer life expectancy in the general population, the prevalence of both heart- and cancer diseases is increasing. Thus, a larger proportion of cancer patients will have cardiovascular co-morbidity and an increased risk of cardiovascular complications during and after cancer treatment. In this article, the current knowledge on the prevention, monitoring and treatment of cardiotoxicity induced by medical anti-cancer treatment with focus on anthracyclines, trastuzumab and 5-fluorouracil is described.

Bidragets oversatte titel	Management of cardiovascular complications secondary to medical treatment of cancer
Originalsprog	Dansk
Artikelnummer	V04170269
Tidsskrift	Ugeskrift for Laeger
Vol/bind	180
Udgave nummer	7
Antal sider	5
ISSN	0041-5782
Status	Udgivet - 2018

Emneord

Anthracyclines/adverse effects
Antineoplastic Agents/adverse effects
Biomarkers/analysis
Cardiotoxicity/diagnosis
Echocardiography
Electrocardiography
Fluorouracil/adverse effects
Heart Diseases/chemically induced
Humans
Monitoring, Physiologic
Neoplasms/drug therapy
Risk Factors
Trastuzumab/adverse effects

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

http://ugeskriftet.dk/videnskab/haandtering-af-hjertekomplikationer-sekundaert-til-medicinsk-kraeftbehandling

Citationsformater

@article{b1995198e60e46aa84529f1826373054,

title = "H{\aa}ndtering af hjertekomplikationer sekund{\ae}rt til medicinsk kr{\ae}ftbehandling",

abstract = "As the prognoses of both heart and cancer patients have improved along with a longer life expectancy in the general population, the prevalence of both heart- and cancer diseases is increasing. Thus, a larger proportion of cancer patients will have cardiovascular co-morbidity and an increased risk of cardiovascular complications during and after cancer treatment. In this article, the current knowledge on the prevention, monitoring and treatment of cardiotoxicity induced by medical anti-cancer treatment with focus on anthracyclines, trastuzumab and 5-fluorouracil is described.",

keywords = "Anthracyclines/adverse effects, Antineoplastic Agents/adverse effects, Biomarkers/analysis, Cardiotoxicity/diagnosis, Echocardiography, Electrocardiography, Fluorouracil/adverse effects, Heart Diseases/chemically induced, Humans, Monitoring, Physiologic, Neoplasms/drug therapy, Risk Factors, Trastuzumab/adverse effects",

author = "Ann Banke and Anne Polk and Dorte Nielsen and Lars Videb{\ae}k and Ulrik Overgaard and Fosb{\o}l, {Emil Loldrup} and Merete Vaage-Nielsen and Nielsen, {Kirsten Melgaard} and Morten Schou",

year = "2018",

language = "Dansk",

volume = "180",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "7",

}

TY - JOUR

T1 - Håndtering af hjertekomplikationer sekundært til medicinsk kræftbehandling

AU - Banke, Ann

AU - Polk, Anne

AU - Nielsen, Dorte

AU - Videbæk, Lars

AU - Overgaard, Ulrik

AU - Fosbøl, Emil Loldrup

AU - Vaage-Nielsen, Merete

AU - Nielsen, Kirsten Melgaard

AU - Schou, Morten

PY - 2018

Y1 - 2018

N2 - As the prognoses of both heart and cancer patients have improved along with a longer life expectancy in the general population, the prevalence of both heart- and cancer diseases is increasing. Thus, a larger proportion of cancer patients will have cardiovascular co-morbidity and an increased risk of cardiovascular complications during and after cancer treatment. In this article, the current knowledge on the prevention, monitoring and treatment of cardiotoxicity induced by medical anti-cancer treatment with focus on anthracyclines, trastuzumab and 5-fluorouracil is described.

AB - As the prognoses of both heart and cancer patients have improved along with a longer life expectancy in the general population, the prevalence of both heart- and cancer diseases is increasing. Thus, a larger proportion of cancer patients will have cardiovascular co-morbidity and an increased risk of cardiovascular complications during and after cancer treatment. In this article, the current knowledge on the prevention, monitoring and treatment of cardiotoxicity induced by medical anti-cancer treatment with focus on anthracyclines, trastuzumab and 5-fluorouracil is described.

KW - Anthracyclines/adverse effects

KW - Antineoplastic Agents/adverse effects

KW - Biomarkers/analysis

KW - Cardiotoxicity/diagnosis

KW - Echocardiography

KW - Electrocardiography

KW - Fluorouracil/adverse effects

KW - Heart Diseases/chemically induced

KW - Humans

KW - Monitoring, Physiologic

KW - Neoplasms/drug therapy

KW - Risk Factors

KW - Trastuzumab/adverse effects

M3 - Tidsskriftartikel

C2 - 29465031

SN - 0041-5782

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 7

M1 - V04170269

ER -

Håndtering af hjertekomplikationer sekundært til medicinsk kræftbehandling

Abstract

Emneord

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater